A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Relapsed/Refractory Myelodysplastic Syndromes (MDS)

  • STATUS
    Not Recruiting
  • participants needed
    68
  • sponsor
    AbbVie
Updated on 20 August 2022
Investigator
AbbVie_Call Center
Primary Contact
Universitaetsklinikum Carl Gus /ID# 154898 (7.4 mi away) Contact
+22 other location
decitabine
bone marrow procedure
azacitidine

Summary

This is a Phase 1b, open-label, multicenter study designed to evaluate the safety and pharmacokinetics of venetoclax as a single-agent and in combination with azacitidine in participants with relapsed/refractory Myelodysplastic Syndromes (MDS).

Details
Condition Preleukemia, MYELODYSPLASTIC SYNDROME
Treatment Azacitidine, venetoclax
Clinical Study IdentifierNCT02966782
SponsorAbbVie
Last Modified on20 August 2022

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note